Levels of circulating tumor cells and of prostate specific antigen were reduced by a new drug in patients who had already failed previous chemotherapy and hormone treatments.
Many persons who receive chemotherapy for incurable cancers may not understand that the treatment is unlikely to be curative.
Two separate research teams identified genes that can predict outcomes in men with castration-resistant prostate cancer (CRPC).
Administering radiotherapy after prostatectomy helped nearly two-thirds of users in a recent study remain free of prostate cancer after 10 years.
A combination of chemotherapy and immunotherapy appears to be a labor-intensive but feasible treatment for persons with metastatic melanoma.
An intrauterine device releasing the progestin levonorgestrel was effective therapy for early endometrial cancer in women not fit for surgery.
A therapeutic vaccine for women who are already harboring human papillomavirus (HPV) appeared to fight cervical cancer in a small, phase 1 study.
Scientists discovered PARP-1 contributes to the growth and progression of androgen receptor-positive prostate cancer cells.
Nelfinavir, a protease inhibitor used in the treatment of HIV, has been found to inhibit the growth of HER2-positive tumors in mice.
New insights into the action of taxanes on androgen receptors in prostate cancer shed light on why a patient may not respond to these drugs.
